

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,657	91.6%	20,368	92.2%	2,027	88.0%	1,986	90.8%	133	89.9%	3,037	87.2%
Epidermoid carcinoma ^d (8051-8131)	195	0.7%	154	0.7%	18	0.8%	21	1.0%	-	-	34	1.0%
Adenocarcinoma ^e	22,673	84.2%	18,826	85.2%	1,761	76.5%	1,838	84.0%	120	81.1%	2,749	78.9%
Adenocarcinoma, NOS (8140)	3,016	11.2%	2,435	11.0%	380	16.5%	169	7.7%	16	10.8%	322	9.2%
Papillary adenocarcinoma, NOS (8050,8260)	300	1.1%	249	1.1%	34	1.5%	-	-	-	-	40	1.1%
Clear cell adenocarcinoma (8310,9110)	1,449	5.4%	1,097	5.0%	67	2.9%	271	12.4%	-	-	159	4.6%
Endometrioid carcinoma (8380-8383,8570)	2,665	9.9%	2,202	10.0%	133	5.8%	302	13.8%	-	-	406	11.7%
Cystadenocarcinoma, NOS (8440,8450)	76	0.3%	59	0.3%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	7,000	26.0%	5,936	26.9%	509	22.1%	467	21.4%	48	32.4%	746	21.4%
Papillary serous cystadenocarcinoma (8460-8462)	5,360	19.9%	4,563	20.6%	434	18.8%	320	14.6%	24	16.2%	662	19.0%
Mucinous cystadenocarcinoma (8470-8473)	356	1.3%	283	1.3%	23	1.0%	46	2.1%	-	-	50	1.4%
Mucinous adenocarcinoma (8480,8482)	999	3.7%	783	3.5%	85	3.7%	112	5.1%	-	-	144	4.1%
Mucin-producing adenocarcinoma(8481)	31	0.1%	23	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,421	5.3%	1,196	5.4%	82	3.6%	130	5.9%	-	-	204	5.9%
Other specific carcinomas ^g	640	2.4%	454	2.1%	132	5.7%	42	1.9%	-	-	103	3.0%
Stromal cell tumor	453	1.7%	309	1.4%	107	4.6%	26	1.2%	-	-	76	2.2%
Other ^h	187	0.7%	145	0.7%	25	1.1%	16	0.7%	-	-	27	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,149	4.3%	934	4.2%	116	5.0%	85	3.9%	-	-	151	4.3%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

Other subgroup of other specific carcinomas includes histologies

8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	86	0.3%	58	0.3%	18	0.8%	-	-	-	-	19	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,867	6.9%	1,439	6.5%	213	9.2%	175	8.0%	-	-	385	11.1%
Mullerian mixed tumor (8950-8951,8980)	828	3.1%	701	3.2%	66	2.9%	48	2.2%	-	-	87	2.5%
Teratoma, malignant (9080-9085,9102)	414	1.5%	274	1.2%	65	2.8%	59	2.7%	-	-	150	4.3%
Other	625	2.3%	464	2.1%	82	3.6%	68	3.1%	-	-	148	4.3%
Unspecified (8000-8005)	303	1.1%	232	1.0%	45	2.0%	18	0.8%	-	-	41	1.2%
Total ^d	26,913	100.0%	22,097	100.0%	2,303	100.0%	2,187	100.0%	148	100.0%	3,482	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic not shown due to fewer than 16 cases during the time period.